SLS vs ZBH
SELLAS Life Sciences Group, Inc. vs Zimmer Biomet — AI-powered side-by-side comparison
SLS
SELLAS Life Sciences Group, Inc.
57
Watch
VS
| Metric | SLS | ZBH |
|---|
| AI Score |
57
|
69
|
| Price |
$11.03
|
$97.22
|
| P/E Ratio |
-52.30×
|
23.54×
|
| ROE |
-37.9%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
69.9%
|
| Debt / Equity |
0.01×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
43.9
|
63.1
|
| Beta |
2.494
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for SLS versus ZBH.
ZBH leads by 12 points.
ZBH scores 69/100 (Buy) versus SLS at 57/100 (Watch).
SLS Committee View
80% agreement
5 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 7.6x prices in significant intangible value — Value
- ROE of only -47.1% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical